Skip to main content
Premium Trial:

Request an Annual Quote

IMDx Assays for Abbott Platform Gain Licensure in Canada, Singapore

NEW YORK (GenomeWeb) — IMDx said today that it has received three additional licenses for sale and distribution of its molecular tests for the Abbott m2000 platform outside the US and EU.

First, the IMDx C. difficile assay for the qualitative detection of toxigenic Clostridium difficile toxin A and B genes, and the Flu A/B and RSV assay for the qualitative detection of influenza A, influenza B, and respiratory syncytial virus have been approved by Health Canada for sale and distribution in Canada.

In addition, the IMDx C. difficile assay has been approved by the Health Sciences Authority for sale and distribution in Singapore, IMDx said.

These tests join the previously licensed IMDx VanR for Abbott m2000 assay in the company's portfolio of tests commercially available in Canada and Singapore.

IMDx, based in Waltham, Mass., has been developing real-time tests for the Abbott m2000 testing system under a multi-year agreement signed between the companies in 2011.

Several such tests have already been CE marked or approved by the US Food and Drug Administration, and IMDx said this week that it has been placing "significant focus" on obtaining international licenses to globally distribute and sell these products.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.